TearOptix Secures Strategic Funding to Transform Presbyopia Treatment and Announces Creation of Scientific Advisory Board
TearOptix, Inc., a pioneering contact lens company developing advanced solutions for patients with presbyopia, today announced the completion of a strategic corporate financing round led by investors with deep expertise in ophthalmology. Presbyopia is the gradual loss of the eye’s ability to focus on nearby objects, affecting virtually everyone over the age of 40. The company also unveiled its distinguished Scientific Advisory Board, which is composed of globally recognized leaders in vision science, clinical ophthalmology and optical engineering.
